Cumulus Neuroscience Announces Publication in Scientific Reports Demonstrating the NeuLogiq® Platform Is Feasible and Usable for At-Home, Multimodal Cognitive Assessment in People Living with ALS and FTD
Source: PR Newswire UK· August 18, 2026
SynaBot summary
Cumulus Neuroscience's NeuLogiq platform has proven effective for at-home cognitive testing in individuals with ALS and FTD. The study, published in Scientific Reports, highlights the system's usability even with severe motor and cognitive challenges.
Key takeaways
- At-home cognitive assessment platform validated for ALS and FTD patients
- High usability reported, even with significant impairment
- NeuLogiq platform shows feasibility for remote multimodal testing
- AI's role in accessible healthcare monitoring expanding
Why it matters
This development is significant for AI tool users as it demonstrates advanced AI's capability in sensitive healthcare applications. It suggests potential for AI-driven remote monitoring and personalized health management tools that can adapt to user limitations.
This story was reported by PR Newswire UK. Read the full original article:
Read on PR Newswire UK 
